FY2024 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Equities researchers at Zacks Research dropped their FY2024 earnings per share estimates for Bruker in a report released on Monday, December 23rd. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.39 for the year, down from their prior estimate of $2.40. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.52 EPS, Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $0.71 EPS, FY2025 earnings at $2.76 EPS, Q3 2026 earnings at $0.81 EPS and FY2026 earnings at $3.41 EPS.

Other equities research analysts have also recently issued reports about the stock. Citigroup decreased their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a report on Thursday, December 5th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. UBS Group began coverage on Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price for the company. Finally, TD Cowen lowered their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $74.45.

Bruker Trading Up 1.5 %

NASDAQ BRKR opened at $58.25 on Wednesday. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The firm has a 50 day moving average of $57.79 and a two-hundred day moving average of $62.33. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $8.83 billion, a PE ratio of 28.00, a price-to-earnings-growth ratio of 4.00 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter in the previous year, the business posted $0.74 EPS. The business’s quarterly revenue was up 16.4% compared to the same quarter last year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker’s dividend payout ratio is currently 9.62%.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien acquired 100,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its position in Bruker by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 966,069 shares of the medical research company’s stock valued at $61,645,000 after buying an additional 27,870 shares during the last quarter. State of Michigan Retirement System boosted its holdings in shares of Bruker by 3.1% in the second quarter. State of Michigan Retirement System now owns 23,493 shares of the medical research company’s stock valued at $1,499,000 after acquiring an additional 700 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Bruker by 114.8% during the second quarter. Allspring Global Investments Holdings LLC now owns 139,486 shares of the medical research company’s stock worth $8,901,000 after acquiring an additional 74,541 shares during the period. Sivik Global Healthcare LLC purchased a new position in Bruker during the second quarter worth about $2,552,000. Finally, Hantz Financial Services Inc. acquired a new stake in Bruker in the second quarter valued at about $694,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.